EAST BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company will release financial results for the second quarter 2011 prior to the open of the market on Thursday, August 4, 2011.
John H. Johnson, Chief Executive Officer and President, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on August 4, 2011, to discuss these results and to answer questions.
To participate by telephone, please dial 877-278-8171 (Domestic) or 574-941-7303 (International). The conference ID number is 84217509. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A telephone replay will be available from 12:00 p.m. Eastern Time on August 4, 2011, through 12:00 a.m. Eastern Time on August 14, 2011, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 84217509.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved